Armstrong Fleming & Moore’s Eli Lilly LLY Stock Holding History

Armstrong Fleming & Moore’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Hold	929	–	–	0.37%	40
2026 Q1	$855K	Buy	929 +33	+4%	+$33.5K	0.36%	45
2025 Q4	$963K	Hold	896	–	–	0.45%	37
2025 Q3	$684K	Buy	896 +140	+19%	+$104K	0.33%	47
2025 Q2	$590K	Buy	756 +501	+196%	+$389K	0.32%	51
2025 Q1	$211K	Sell	255 -501	-66%	-$417K	0.26%	75
2024 Q4	$584K	Hold	756	–	–	0.35%	45
2024 Q3	$670K	Sell	756 -74	-9%	-$66.5K	0.39%	44
2024 Q2	$752K	Buy	830 +13	+2%	+$10.4K	0.48%	40
2024 Q1	$636K	Buy	817 +57	+8%	+$40.6K	0.44%	42
2023 Q4	$443K	Hold	760	–	–	0.33%	60
2023 Q3	$408K	Hold	760	–	–	0.4%	56
2023 Q2	$357K	Buy	+760	New	+$319K	0.33%	61

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armstrong Fleming & Moore's LLY Position: Q2 2026 in Review

Armstrong Fleming & Moore held its Eli Lilly (LLY) position steady in Q2 2026 at 929 shares worth $1.11M. The position accounts for 0.37% of the portfolio, ranked #40.

Armstrong Fleming & Moore first reported a position in LLY in Q2 2023 and has held it in 13 quarters since. 4,623 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Armstrong Fleming & Moore held 929 shares of Eli Lilly worth $1.11M as of Q2 2026.
Armstrong Fleming & Moore left its Eli Lilly share count unchanged in Q2 2026.
Eli Lilly made up 0.37% of Armstrong Fleming & Moore's portfolio in Q2 2026, its #40 holding.
Armstrong Fleming & Moore first reported a position in Eli Lilly in Q2 2023 and has held it in 13 quarters since.
4,623 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q2 2026, filed 28 Jul 2026.